Esperion Therapeutics (ESPR) Stock Analysis

What Esperion Therapeutics does

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.

Key metrics

ETFs linked to ESPR

Broad-market and Healthcare sector ETFs an investor holding Esperion Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ESPR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Esperion Therapeutics?

Esperion Therapeutics trades under the ticker ESPR on NASDAQ.

Which exchange is ESPR listed on?

ESPR is listed on NASDAQ.

What sector does Esperion Therapeutics operate in?

Esperion Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ESPR in a portfolio?

PortView shows ESPR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.